TRMT6

Across TCGA pan-cancer cohorts, TRMT6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRMT6 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher TRMT6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRMT6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCS, UCEC, and COAD are the cancer types where TRMT6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.104	0.688	<.001	36	view →
UCEC	DFS	Median	All	1.000	0.827	.008	32	view →
COAD	OS	Median	All	0.181	0.806	.002	6	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	3	view →
SKCM	OS	Median	III,IV	0.344	0.710	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRMT6–UCS (OS)

Open the UCS breakdown →